Histology-agnostic drug development - considering issues beyond the tissue

Area of Science:

• Oncology
• Molecular Biology
• Immunology
• Drug Development

Background:

• Advances in cancer biology and immunology enable targeted therapies based on molecular alterations and immune phenotypes, irrespective of tumor histology.
• Landmark approvals of pembrolizumab (high microsatellite instability) and larotrectinib/entrectinib (NTRK fusions) established a pathway for histology-agnostic indications.

Purpose of the Study:

• To review the development and testing of approved histology-agnostic cancer therapies.
• To present data on other agents currently under development.
• To discuss the biological, regulatory, design, and statistical challenges in histology-agnostic drug development.

Main Methods:

• Review of approved histology-agnostic therapeutic agents.
• Summary of data on agents currently in development.
• Discussion of challenges in clinical trial design, patient selection, statistical analysis, and regulatory frameworks.

Main Results:

• Approved histology-agnostic therapies demonstrate the feasibility of this approach.
• Negative trial results highlight complexities in patient selection and statistical analysis across heterogeneous histologies.
• Ongoing development shows continued interest and investment in this therapeutic strategy.

Conclusions:

• Histology-agnostic drug development offers a promising paradigm shift in precision oncology.
• Overcoming challenges in trial design, statistical analysis, and regulatory adaptation is crucial for future success.
• Further optimization of the regulatory framework is needed to effectively utilize post-approval data.